Pub Date : 2007-09-01DOI: 10.1016/S1594-5804(08)60009-1
A. Di Sabatino, P. Cazzola, R. Ciccocioppo, R. Morera, P. Biancheri, L. Rovedatti, L. Cantoro, A. Vanoli, F.P. Tinozzi, S. Tinozzi, G.R. Corazza
Background
Butyrate exerts anti-inflammatory effects in experimental colitis and in lamina propria mononuclear cells of patients with Crohn's disease.
Aims
To assess the safety and efficacy of butyrate in Crohn's disease.
Patients
Thirteen patients with mild to moderate Crohn's disease were treated with enteric-release sodium butyrate tablets at a dosage of 4 g/day for eight weeks.
Methods
Before and after treatment, patients underwent coloscopy with evaluation of the clinical activity of their disease, systemic inflammation index and mucosal expression of interleukin (IL)-1β, IL-6, IL-12, interferon (IFN)-γ, tumour necrosis factor (TNF)-α and nuclear factor (NF)-κB.
Results
Of the nine patients (69%) responding to treatment, 7 (53%) exhibited complete response and 2 exhibited partial response. Endoscopic and histological evaluation scores were significantly improved (p < 0.05) and significant reductions were seen after treatment in white cell count, erythrocyte sedimentation rate (ESR), mucosal concentrations of NF-κB and IL-1β (p < 0.05).
Conclusions
Oral administration of butyrate may be effective in inducing clinical improvement or remission in patients with Crohn's disease.
{"title":"Efficacy of butyrate in the treatment of mild to moderate Crohn's disease","authors":"A. Di Sabatino, P. Cazzola, R. Ciccocioppo, R. Morera, P. Biancheri, L. Rovedatti, L. Cantoro, A. Vanoli, F.P. Tinozzi, S. Tinozzi, G.R. Corazza","doi":"10.1016/S1594-5804(08)60009-1","DOIUrl":"10.1016/S1594-5804(08)60009-1","url":null,"abstract":"<div><h3>Background</h3><p>Butyrate exerts anti-inflammatory effects in experimental colitis and in lamina propria mononuclear cells of patients with Crohn's disease.</p></div><div><h3>Aims</h3><p>To assess the safety and efficacy of butyrate in Crohn's disease.</p></div><div><h3>Patients</h3><p>Thirteen patients with mild to moderate Crohn's disease were treated with enteric-release sodium butyrate tablets at a dosage of 4 g/day for eight weeks.</p></div><div><h3>Methods</h3><p>Before and after treatment, patients underwent coloscopy with evaluation of the clinical activity of their disease, systemic inflammation index and mucosal expression of interleukin (IL)-1β, IL-6, IL-12, interferon (IFN)-γ, tumour necrosis factor (TNF)-α and nuclear factor (NF)-κB.</p></div><div><h3>Results</h3><p>Of the nine patients (69%) responding to treatment, 7 (53%) exhibited complete response and 2 exhibited partial response. Endoscopic and histological evaluation scores were significantly improved (<em>p</em> < 0.05) and significant reductions were seen after treatment in white cell count, erythrocyte sedimentation rate (ESR), mucosal concentrations of NF-κB and IL-1β (<em>p</em> < 0.05).</p></div><div><h3>Conclusions</h3><p>Oral administration of butyrate may be effective in inducing clinical improvement or remission in patients with Crohn's disease.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":"1 1","pages":"Pages 31-35"},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60009-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77594577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-09-01DOI: 10.1016/S1594-5804(08)60006-6
E. Scarpellini, E.C. Lauritano, A. Lupascu, C. Petruzzellis, M.L. Novi, D. Roccarina, M. Gabrielli, M. Serricchio, G. Gasbarrini, A. Gasbarrini
Introduction
Short-chain fatty acids affect enterocyte metabolism and differentiation. Butyric acid in particular is already used in ulcerative rectal colitis, pouchitis and antibiotic-induced diarrhoea.
Aims
To assess the efficacy of butyrate in the treatment of irritable bowel syndrome (IBS).
Patients
Fifty patients with IBS were treated using enteric-coated sodium butyrate tablets at a dosage of 1 g/day for 30 days.
Methods
The patients were divided into two subgroups: constipation-predominant IBS and diarrhoea-predominant IBS. The IBS variant and symptom scores of patients were recorded before and after treatment.
Results
Treatment with butyric acid reduced in normalisation of status in 68% and 71% of patients in the diarrhoea-predominant IBS group vs. 14% and 16% of patients in the constipation-predominant IBS group (respectively for the intent-to-treat and per-protocol analyses) (p < 0.005). The symptoms score for abdominal pain, meteorism and flatulence was significantly improved in patients with the diarrhoea variant compared with those with the constipation variant (p < 0.05).
Conclusions
Oral administration of butyrate may be effective in regulating status and improving gastrointestinal symptoms in patients with the diarrhoea-predominant irritable bowel syndrome.
{"title":"Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome","authors":"E. Scarpellini, E.C. Lauritano, A. Lupascu, C. Petruzzellis, M.L. Novi, D. Roccarina, M. Gabrielli, M. Serricchio, G. Gasbarrini, A. Gasbarrini","doi":"10.1016/S1594-5804(08)60006-6","DOIUrl":"10.1016/S1594-5804(08)60006-6","url":null,"abstract":"<div><h3>Introduction</h3><p>Short-chain fatty acids affect enterocyte metabolism and differentiation. Butyric acid in particular is already used in ulcerative rectal colitis, pouchitis and antibiotic-induced diarrhoea.</p></div><div><h3>Aims</h3><p>To assess the efficacy of butyrate in the treatment of irritable bowel syndrome (IBS).</p></div><div><h3>Patients</h3><p>Fifty patients with IBS were treated using enteric-coated sodium butyrate tablets at a dosage of 1 g/day for 30 days.</p></div><div><h3>Methods</h3><p>The patients were divided into two subgroups: constipation-predominant IBS and diarrhoea-predominant IBS. The IBS variant and symptom scores of patients were recorded before and after treatment.</p></div><div><h3>Results</h3><p>Treatment with butyric acid reduced in normalisation of status in 68% and 71% of patients in the diarrhoea-predominant IBS group vs. 14% and 16% of patients in the constipation-predominant IBS group (respectively for the intent-to-treat and per-protocol analyses) (p < 0.005). The symptoms score for abdominal pain, meteorism and flatulence was significantly improved in patients with the diarrhoea variant compared with those with the constipation variant (p < 0.05).</p></div><div><h3>Conclusions</h3><p>Oral administration of butyrate may be effective in regulating status and improving gastrointestinal symptoms in patients with the diarrhoea-predominant irritable bowel syndrome.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":"1 1","pages":"Pages 19-22"},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60006-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88264913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-09-01DOI: 10.1016/S1594-5804(08)60005-4
G. D'Argenio, G. Mazzone, N. Caporaso
Background
Note that butyrate is utilised by colonocytes in energy production and that deficiency of this substance is observed in the colon of patients with chronic inflammatory bowel disease.
Aims
We first assessed the efficacy of butyrate in rats with induced colitis, and since this condition represents a condition of increased risk of colonic neoplasia, we also evaluated whether butyrate treatment reduces susceptibility of the mucosa to the emergence of carcinoma in the colon of rats with experimental colitis.
Materials and methods
Colitis was induced with trinitrobenzene-sulphonic acid and colonic tumours were induced with azoxymethane.
Results
Colitis improved noticeably following treatment with butyrate and tumours emerging in colitis were significantly reduced in both size and number.
Conclusions
The results obtained suggest the need for further study of the metabolic fate of butyrate and its role in maintaining the mucosal integrity of the colon.
{"title":"Butyrate in the treatment of experimental models of colitis","authors":"G. D'Argenio, G. Mazzone, N. Caporaso","doi":"10.1016/S1594-5804(08)60005-4","DOIUrl":"10.1016/S1594-5804(08)60005-4","url":null,"abstract":"<div><h3>Background</h3><p>Note that butyrate is utilised by colonocytes in energy production and that deficiency of this substance is observed in the colon of patients with chronic inflammatory bowel disease.</p></div><div><h3>Aims</h3><p>We first assessed the efficacy of butyrate in rats with induced colitis, and since this condition represents a condition of increased risk of colonic neoplasia, we also evaluated whether butyrate treatment reduces susceptibility of the mucosa to the emergence of carcinoma in the colon of rats with experimental colitis.</p></div><div><h3>Materials and methods</h3><p>Colitis was induced with trinitrobenzene-sulphonic acid and colonic tumours were induced with azoxymethane.</p></div><div><h3>Results</h3><p>Colitis improved noticeably following treatment with butyrate and tumours emerging in colitis were significantly reduced in both size and number.</p></div><div><h3>Conclusions</h3><p>The results obtained suggest the need for further study of the metabolic fate of butyrate and its role in maintaining the mucosal integrity of the colon.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":"1 1","pages":"Pages 13-17"},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60005-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83489713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号